Johnson & Johnson Stock News

Shares of Legend Biotech Corp. were up 8.6% in premarket trading on Tuesday, the day after the company said that the Food and Drug Administration had approved the CAR-T therapy it developed with Johnson & Johnson as a multiple myeloma treatment. J&J''s stock was down 0.8% in premarket trading on Tuesday. Legend had inked the licensing and collaboration deal with J&J back in 2017. The treatment is approved for adults with relapsed or refractory multiple myeloma who have already received four lines of treatment. The "approval of Carvykti is a pivotal moment for Legend Biotech because it is our first-ever marketing approval, but what really excites us is the drug''s potential to become an impactful therapy option for patients in need of long, treatment-free intervals," Ying Huang, Legend''s CEO and CFO, said in a news release. Legend''s stock has soared 49.8% over the past year, while the broader S&P 500 is up 14.7%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move.

The U.S. Food and Drug Administration ((FDA)) approved Johnson & Johnson (JNJ) and Legend Biotech''s (LEGN) CAR-T therapy Carvykti to treat adults with relapsed or refractory…

The U.S. health regulator has approved a therapy developed by Johnson & Johnson and its China-focused partner Legend Biotech Corp to treat a type of white blood cell cancer, the U.S. healthcare company said on Monday.

Johnson & Johnson acquired rights to the new drug and conducted studies in the U.S. confirming it worked safely.

Johnson & Johnson acquired rights to the new drug and conducted studies in the U.S. confirming it worked safely.

Las Vegas, USA, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Global Dengue Fever Pipeline Insights | Clinical Trials Evaluation Research Report 2022 by DelveInsight Dengue Fever Pipeline constitutes 20+ key companies continuously working towards developing 20+ Dengue Fever treatment therapies, analyzes DelveInsight DelveInsight''s ‘ Dengue Fever Pipeline Insight 2022'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Dengue Fever pipeline domain. Some of the essential takeaways from the Dengue Fever Pipeline report: DelveInsight''s Dengue Fever Pipeline analysis depicts a robust space with 20+ active players proactively working to develop 20+ pipeline treatment therapies. Some of the key Dengue companies working to develop potential drug candidates to improve the Dengue Fever treatment scenario include Kino Pharma, Emergex Vaccines, Abivax, Plex Pharmaceuticals, Takeda, Merck Sharp & Dohme, Immunoforge, Chugai Pharmaceutical Co., Ltd, Codagenix, Biotron Ltd, GlaxoSmithKline, Ennaid therapeutics, AbViro LLC, Medigen Vaccine Biologics Corp., Atea Pharmaceuticals, Visterra, Janssen Research & Development, Globavir Biosciences, Serum Institute of India, BioNet Asia, and many others.

In a federal bankruptcy court in Trenton, New Jersey, Judge Michael Kaplan ruled in favor of Johnson & Johnson''s (NYSE: JNJ ) controversial bankruptcy filing meant to settle 38,000 claims alleging its talc-based products caused cancer. According to the Wall Street Journal report, the ruling will allow a J&J subsidiary, LTL Management, to proceed with its chapter 11 filing and … Full story available on Benzinga.com

New Zealand High Court: Vaccine Mandate Not "Demonstrably Justified", Breach Of Rights Authored by Katabella Robert via The Epoch Times (emphasis ours), The New Zealand High Court has upheld a challenge to a vaccine mandate for Police and Defence Force staff, stating that it was not a “demonstrably justified” breach of the Bill of Rights. Police stop vehicles to heading north on state highway one at Warkworth in Auckland, New Zealand, on April 09, 2020. (Fiona Goodall/Getty Images) Justice Francis Cooke was asked by a group of Police and Defence Force personnel to judicially review the vaccine mandate enacted under the COVID-19 Public Health Response Act in December. The mandate required all Defence Force personnel and all Police constables, recruits, and authorized officers to receive two doses of the vaccine by March 1. But on Jan. 6, three unvaccinated staff who did not wish to receive the shots sought a judicial review of the mandate. They were supported by affidavits from 37 of their colleagues in the same position.

Drug distributors McKesson, AmerisourceBergen and Cardinal Health are part of the settlement.

Growing Number Of Experts Call On US Govt To Recognize Natural Immunity Authored by Zachary Stieber via The Epoch Times, A growing number of experts are urging the U.S. government to formally recognize natural immunity , or the protection given by recovering from COVID-19 . More experts are arguing that the Centers for Disease Control and Prevention’s (CDC) recommended vaccination schedule should feature fewer doses—or none at all—for people who have contracted COVID-19 and survived. “Natural infection should count as two doses,” Dr. Paul Offit, professor of pediatrics at the Children’s Hospital of Philadelphia, and an adviser to the Food and Drug Administration on vaccines, told The Epoch Times. Offit and two former FDA officials stated in a recent op-ed that “requiring people who have been infected to get three shots is overkill at best—a waste of valuable doses—and an unnecessary risk at worst (given that vaccines have side effects, albeit rare ones).” Under current CDC guidance, all Americans 12 and older are advised to get three doses of the Moderna or Pfizer COVID-19 vaccines.

California is expected to receive $2.05 billion, while the City of Los Angeles could get "tens of millions" from the settlement.

© Reuters. The company logo for Johnson & Johnson is displayed to celebrate the 75th anniversary of the company’s listing at the New York Stock Exchange (NYSE) in New York, U.S., September 17, 2019. REUTERS/Brendan McDermid By Dietrich Knauth and Tom Hals (Reuters) -Johnson & Johnson can use the bankruptcy system to resolve multibillion-dollar litigation …